Latest news
Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 17:19:41 GMTThe Weight-Loss Drug Biohackers Now Swear Extends Your Life - ELLEELLE · Fri, 31 Jul 2026 17:34:11 GMTPhase 3 Trials Show Weight Loss for Triple Agonist with OSA Potential - Sleep ReviewSleep Review · Tue, 28 Jul 2026 17:18:03 GMT